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background: Permanent pacemaker implantation (PPI) is common after transcatheter aortic valve replacement (TAVR), but there are limited data 
about this complication. We investigated the clinical long-term outcomes in patients receiving PPI after TAVR with Medtronic CoreValve (MCV) and 
Edwards Sapien XT (EXT).
Methods: TAVR was performed in 172 high-risk patients with severe aortic stenosis (age: 79.8±7.2 years; logistic EuroSCORE 23.7±11.7%; 
60% females; NYHA III 83%; aortic valve mean gradient 49.9±15.3mmHg, 66% MCV) who did not have a previous pacemaker. Prosthesis-patient 
mismatch (PPM) was defined as indexed effective orifice area (EOAi) ≤0.85cm2/m2, severe if EOAi ≤0.65cm2/m2. Composite end points and major 
vascular complications (MVC) were considered as per the VARC-2 criteria.
results: Procedural success rate was 86% in the entire cohort. Fifty-three patients (31%) in total received a PPI post TAVR; in 48 MCV was 
implanted and in 5 an EXT (91% vs 9%, p<0.001). Patients receiving a pacemaker had a longer hospital stay (6.5±3.7 days vs 6.1±4 days, p<0.5), 
higher logEuroSCORE (25.3±11.3% vs 23±12%, p<0.2), had a smaller body mass index (24.2±5kg/m2 vs 26.4±4.2, p<0.004) and a higher body 
surface area (5±8.2 m2 vs 3.1±5.6, p<0.08). Patients with PPI had severe PPM compared to those without PPI (15% vs 5.4%, p<0.09) and suffered 
less MVC (8.6% vs 9.4%, p< 0.5). 30-day survival was 98.1% for patients with PPI and 97.4% for those without (p<0.5). One-year survival was higher 
for patients without PPI, but the difference was not statistical significant (94% vs 92.5%, p<0.7).
conclusion: Pacemaker implantation does not have a negative impact on outcomes and survival in patients undergoing TAVR with MCV and EXT.
